Last reviewed · How we verify
Rifamycine
Rifamycine is a Small molecule drug developed by Yuzuncu Yil University. It is currently FDA-approved. Also known as: RIF 250 MG IM Ampul.
Rifamycine is a small molecule antibiotic that is effective against mycobacteria, used to treat conditions such as tuberculosis and leprosy. It is a subclass of the ansamycin family, synthesized either naturally or artificially, and is known to induce CYP3A4, as seen in its interaction with other drugs.
At a glance
| Generic name | Rifamycine |
|---|---|
| Also known as | RIF 250 MG IM Ampul |
| Sponsor | Yuzuncu Yil University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea (PHASE4)
- Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers (PHASE1)
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifamycine CI brief — competitive landscape report
- Rifamycine updates RSS · CI watch RSS
- Yuzuncu Yil University portfolio CI
Frequently asked questions about Rifamycine
What is Rifamycine?
Who makes Rifamycine?
Is Rifamycine also known as anything else?
What development phase is Rifamycine in?
Related
- Manufacturer: Yuzuncu Yil University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: RIF 250 MG IM Ampul
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing